The antiviral resistance report

Results are provided as:

Results on phenotyping are expressed as EC₅₀ values (50% effective concentration) for each compound not only for the patient sample but also for the corresponding reference laboratory strains.
Results on genotyping are provided as gene mutations associated with antiviral resistance or genetic polymorphism.

Additionally, an interpretation of the results, conclusions and guidelines for treatment are included in the reports.

Different types of reports are provided:

Intermediate reports (in a couple of days) that will help to adjust the antiviral treatment.

In the case of CMV genotyping, a preliminary screening will be performed to detect the presence of mutations in the UL97 gene that are known to confer resistance to ganciclovir. In a second step, the complete sequencing of the UL97 and UL54 genes will be determined.
Similary to CMV, for HHV-6 a preliminary screening will be done to verify the presence of mutations in the U69 gene that are known to be linked to ganciclovir resistance. In a following phase, the entire sequencing of the U69 and U38 genes will be carried out.
When HSV antiviral resistance is requested, results on phenotyping will be provided in an initial report in 3-4 days. A definitive report including determination of mutations in the viral TK and DNA polymerase genes will be given if antiviral resistance was detected phenotypically.
If antiviral resistance is demanded, genotyping of the viral thymidine kinase will be performed firstly and the results will be provided in a preliminary report. In a next step, we will do the genotyping of the viral DNA polymerase and phenotyping if the virus can be isolated.

Definitive reports that include the complete sequencing of the gene(s) of interest and phenotyping when virus growth is feasible.
Additional reports that include phenotyping of genotypically characterized CMV or VZV mutants in case the virus isolate grows in vitro.

Download examples of a RegaVir report here: